Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports

Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing ≥50% expression of programmed death-ligand 1 (PD-L1). Previously it was reported that platinum-based chemotherapy may change...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Toshiaki, Tateishi, Akiko, Bychkov, Andrey, Fukuoka, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566896/
https://www.ncbi.nlm.nih.gov/pubmed/31130676
http://dx.doi.org/10.3390/ijms20102578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566896/
https://www.ncbi.nlm.nih.gov/pubmed/31130676
http://dx.doi.org/10.3390/ijms20102578

Ejemplares similares